Acellular Dermal Matrices Market, By Origin (Human Dermis, Porcine Dermis, and Bovine Dermis), By Application (Acute Wounds (Burns, Trauma, Cancers, and Infections) Chronic Wounds (Diabetic Foot Ulcers, Venous Leg Ulcers, Pressure Ulcer, and Others), and Reconstruction Procedures (Abdominal Wall Procedures, Breast Procedures, Orthopedic Procedures, and Others)), By Place of Setting (Hospitals (in-patient, out-patient), Ambulatory Surgical Centers, and Office Based), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Oct 2023

Code : CMI4362

Pages :271

Formats :

Excel and PDF

Industry : Biotechnology

Market Challenges And Opportunities

Global Acellular Dermal Matrices Market – Drivers

Increasing demand for cosmetic and reconstructive surgeries: Acellular dermal matrices are frequently utilized in plastic and reconstructive surgery including breast reconstruction and facial aesthetics. Growing demand for cosmetic and reconstructive procedures is expected to drive the market growth.
For instance, in 2022, according to the American Society of Plastic Surgeons (ASPS), a non-profit organization, total cosmetic surgery treatments in the U.S. were 576,485 in 2022, indicating increase of 19% from 2019. This total number of breast category operations were 575,492, which increased by 15% from 2019. These surgeries include breast augmentation, breast lift (mastopexy), and breast reductions.
Product launches or approvals: Market players are focusing on product launches of new acellular dermal matrices (ADM), and this is expected to drive the global acellular dermal matrices market growth over the forecast period. For instance, in April 2023, MTF Biologics, a global non-profit organization, launched AlloPatch Pliable Meshed to its portfolio of superior, creative, and effective wound care treatments. AlloPatch Pliable Meshed is an acellular human reticular dermal allograft meant to aid in the healing of difficult-to-heal lesions such as diabetic foot ulcers and venous leg ulcers.

Global Acellular Dermal Matrices Market: Restraint

Regulatory challenges: Stringent regulatory approval processes for medical devices including acellular dermal matrices is expected to hinder the global acellular dermal matrices market growth. For instance, in March 2021, The U.S. Food and Drug Administration (FDA) released a safety communication external site pertaining to Acellular Dermal Matrices (ADM) products used in implant-based breast reconstruction. According to the U.S. FDA's review, two ADMs named FlexHD developed by MTF Biologics, a global non-profit organization and Allomax developed by BD, a medical device company may have a greater risk profile than others. Two years after surgery, there were greater incidence of serious problems, explanation, further procedures, and infections.

To counterbalance the restraint, key players should focus on increasing the safety and efficacy of ADM products.

Regulatory challenges